For monosialotetrahexosylganglioside ( GM-1 ) , one guideline ( 1 / 4 = 0.25 ) recommended for ( consensus-based ) , one ( 1 / 4 = 0.25 ) recommended against ( evidence-based ) , and two ( 2 / 4 = 0.50 ) recommended neither for nor against .